Our Mission
LurexBio is dedicated to engineering next-generation immunotherapies that leverage endogenous biology to target disease with unparalleled precision. By uniting elegant design with translational rigor, we bridge the gap between breakthrough science and life-changing patient outcomes—grounded in a culture of integrity and transparency.
Our Commitment
Proprietary Platforms
Lurex Bio Inc. is a biotechnology company pioneering next-generation immune engineering and therapeutic delivery systems designed to overcome tumor immune evasion.
Our proprietary technology platforms—NeoTag™, Atraxis™, Atraxis-X™, and DeltaGate Logic™— work in concert to reactivate the body's natural defenses against cold tumors that escape immune detection.
By fusing synthetic immune signals directly onto tumor cell membranes, Lurex Bio's systems transform invisible cancer cells into visible targets recognized by the body's own T-cells and natural killer cells.
Our Story
Lurex Bio Inc. was founded with a single purpose—to unlock the body’s own immune potential against cancer. What began as a deeply personal journey has grown into a focused scientific mission shared by researchers, clinicians, and innovators who believe in the promise of immune-driven therapies.
This technology began from humble beginnings. During the course of his long-term treatment foradvanced metastatic prostate cancer (Stage IV), the founder began an intensive study of immunology and emerging therapeutic technologies. Determined to find better answers, he spent years examining the science behind immune evasion and tumor recognition. Over time, those investigations evolved into a novel approach for re-engaging the body’s natural defense mechanisms.
Throughout this process, the founder consulted with scientists and medical professionals who have reviewed the concept and agree that it represents a potential breakthrough—if validated in formal research and clinical studies. Their encouragement and critical insights have guided the refinement of the underlying platform that now defines Lurex Bio’s technology.
Guided by both experience and evidence, Lurex Bio continues to advance its proprietary immunotherapy systems with the goal of transforming how solid-tumor cancers are addressed. Every step forward is driven by the same belief that started it all: that innovation, joined with human determination, can transform impossible odds into new possibilities.
Our Team
Driven by a diverse team of industry veterans, LurexBio combines deep scientific insight with operational excellence to bring precision immunotherapies to the modern clinical landscape.
Scientific Advisory Board
LurexBio is guided by a world-class Scientific Advisory Board with over 200 years of collective experience in delivering blockbuster immunotherapies.
Intellectual Property & Innovation Framework
Lurex Bio’s intellectual property portfolio is represented by Hayes Soloway P.C., a nationally recognized biotechnology patent law firm led by Nick Soloway. The firm provides comprehensive strategic guidance and patent management across all of Lurex Bio’s therapeutic platforms, reflecting a shared commitment to advancing innovation through thoughtful and enduring collaboration.
Latest News
Featured In
